Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals (AVDL) Financial Statements


Avadel Pharmaceuticals Financial Overview

Avadel Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-2.325; its P/E ratio is -6.06; Avadel Pharmaceuticals is scheduled to report earnings on August 8, 2023, and the estimated EPS forecast is $-0.36. See an overview of income statement, balance sheet, and cash flow financials.
Mar 23Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue-$ 116.00K$ 0.00$ 0.00$ 0.00
Gross Profit-$ -3.35M---
EBIT$ -28.30M$ -23.07M$ -16.51M$ -29.75M$ -28.73M
EBITDA$ -25.84M$ -20.58M$ -16.11M$ -29.50M$ -28.47M
Net Income Common Stockholders$ -30.78M$ -27.45M$ -20.15M$ -63.44M$ -26.42M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 100.92M$ 96.50M$ 106.47M$ 104.12M$ 123.48M
Total Assets$ 139.96M$ 132.78M$ 145.76M$ 157.94M$ 221.13M
Total Debt$ 115.16M$ 131.02M$ 138.27M$ 136.51M$ 145.13M
Net Debt$ 14.24M$ 34.52M$ 31.80M$ 32.39M$ 21.64M
Total Liabilities$ 178.91M$ 132.78M$ 158.20M$ 161.27M$ 165.90M
Stockholders Equity$ -38.17M$ -21.14M$ -12.44M$ -3.33M$ 55.23M
Cash Flow-
Free Cash Flow$ -30.23M$ -15.40M$ -7.52M$ -14.09M$ -34.05M
Operating Cash Flow$ -30.23M$ -15.40M$ -6.80M$ -14.09M$ -34.05M
Investing Cash Flow$ 5.07M$ 22.91M$ 2.52M$ 12.05M$ 42.25M
Financing Cash Flow$ 34.44M$ 6.62M$ 10.71M$ -4.80M$ 2.01M
Currency in USD

Avadel Pharmaceuticals Earnings and Revenue History

Avadel Pharmaceuticals Debt to Assets

Avadel Pharmaceuticals Cash Flow

Avadel Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis